This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic tariffs.

A study comparing artificial intelligence (AI)-driven clinical recommendations to physician decision-making for common acute complaints in a virtual primary care setting found that AI support has the ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, ...

On Wednesday, Jim Cramer, the host of Mad Money, shared his concerns about President Donald Trump’s approach to trade and its ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Rigel Pharmaceuticals is now reporting net income and has three marketed drugs, all of which can continue to grow. Read more ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.